← Back to Search

Hsp90 Inhibitor

Gamitrinib for Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Fox Chase Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 years

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions

Solid Tumors
Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determine the MTD and/or RP2D of gamitrinib when administered once weekly.

Secondary outcome measures

Assess the pharmacodynamic effects of gamitrinib

Document any anti-tumor activity of single agent gamitrinib

Evaluate the overall safety profile of intravenously administered single-agent gamitrinib

+5 more

Trial Design

7Treatment groups

Experimental Treatment

Group I: Dose 6Experimental Treatment1 Intervention

Accelerated Phase: 320 mg Standard Phase: 85 mg

Group II: Dose 5Experimental Treatment1 Intervention

Accelerated Phase: 160 mg Standard Phase: 65 mg

Group III: Dose 4Experimental Treatment1 Intervention

Accelerated Phase: 80 mg Standard Phase: 50 mg

Group IV: Dose 3Experimental Treatment1 Intervention

Accelerated Phase: 40 mg Standard Phase: 35 mg

Group V: Dose 2Experimental Treatment1 Intervention

Accelerated Phase: 20 mg Standard Phase: 20 mg

Group VI: Dose 1Experimental Treatment1 Intervention

Accelerated Phase: 10 mg Standard Phase: 10 mg

Group VII: Dose -1Experimental Treatment1 Intervention

Accelerated Phase: - Standard Phase: 5 mg

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,625 Total Patients Enrolled

1,381 Trials studying Lymphoma

382,358 Patients Enrolled for Lymphoma

Fox Chase Cancer CenterLead Sponsor

227 Previous Clinical Trials

37,467 Total Patients Enrolled

13 Trials studying Lymphoma

119 Patients Enrolled for Lymphoma

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,537 Total Patients Enrolled

27 Trials studying Lymphoma

12,963 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Gamitrinib received regulatory approval by the FDA?

"There is minimal evidence to suggest Gamitrinib's safety, thus it earned a score of 1."

Answered by AI

Are any participants being accepted for the current trial at this time?

"According to clinicaltrials.gov, the recruitment process for this medical study is underway; its listing was introduced on November 5th 2021 and updated lastly on February 2nd 2022."

Answered by AI

How many participants have signed up for this research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical study - which was first posted on November 5th 2021 - is currently recruiting patients from a single location and 42 individuals are desired for the trial overall."

Answered by AI

Recent research and studies

Cancer Biology & TherapyJournal

Feasibility and Safety of Targeting Mitochondria for Cancer Therapy – Preclinical Characterization of Gamitrinib, a First-in-class, Mitochondrial-targeted Small Molecule Hsp90 Inhibitor

Hayat, Umar, Gary T. Elliott, Anthony J. Olszanski, and Dario C. Altieri. 2022. “Feasibility and Safety of Targeting Mitochondria for Cancer Therapy – Preclinical Characterization of Gamitrinib, a First-in-class, Mitochondrial-targeted Small Molecule Hsp90 Inhibitor”. Cancer Biology & Therapy. Informa UK Limited. doi:10.1080/15384047.2022.2029132.

clinicaltrials.govStudy

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

2021. "A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04827810.